Signals
Microglia Are Not a Shortcut to Alzheimer’s Certainty
Sanofi’s oral TREM2 agonist SAR448851 is moving toward Phase II testing in early Alzheimer’s disease. The mechanism is compelling. The field has already learned that TREM2 biology can disappoint.
The Money Is Moving Into Cancer Screening. The Evidence Still Has to Catch Up.
Huntington’s Needs More Than a Better Curve
New nicotine products could become the next major cardiovascular policy failure
Childhood obesity is the next cardiometabolic crisis already unfolding
Neurology Is Trying to Stop Nerves Dying, Not Just Treat What Is Left
South Sudan Has a New Health Deal. Now It Needs a Delivery System.
AI Improved Sepsis Compliance. Patients Still Need the Outcome Proof.
Cardiac rehab saves lives. Health systems still treat it like optional aftercare
BMI is not enough. Cardiometabolic risk is hiding in where fat lives
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.